X

Trial Profile

A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 31 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fentanyl (Primary) ; Fentanyl; Morphine; Morphine; Oxycodone
Indications Cancer pain
Focus Registrational; Therapeutic Use
Sponsors Kyowa Hakko Kirin; Kyowa Hakko Kogyo; Kyowa Kirin

Most Recent Events

12 Dec 2013 Manufacturing and marketing approval of Abstral in Japan was received on 20 September 2013, ahead of expectations, and the launch has commenced, according to an Orexo media release.
11 Dec 2013 Abstral was launched in Japan, according to a Kyowa Hakko Kirin media release.
16 Jun 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com